Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 randomized trial of pegylated interferon alfa-2a (PEG) versus hydroxyurea (HU) therapy for the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET) Meeting Abstract


Authors: Mascarenhas, J.; Kosiorek, H. E.; Prchal, J. T.; Rambaldi, A.; Berenzon, D.; Yacoub, A.; Harrison, C. N.; McMullin, M. F.; Vannucchi, A. M.; Ewing, J.; O'Connell, C. L.; Kiladjian, J. J.; Mead, A. J.; Winton, E. F.; Leibowitz, D. S.; De Stefano, V.; Arcasoy, M. O.; Kessler, C. M.; Catchatourian, R.; Rondelli, D.; Silver, R. T.; Bacigalupo, A.; Nagler, A.; Kremyanskaya, M.; Sandy, L.; Salama, M. E.; Najfeld, V.; Tripodi, J.; Weinberg, R. S.; Price, L.; Goldberg, J. D.; Rampal, R. K.; Mesa, R. A.; Dueck, A. C.; Hoffman, R.
Abstract Title: Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 randomized trial of pegylated interferon alfa-2a (PEG) versus hydroxyurea (HU) therapy for the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET)
Meeting Title: 60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 132
Issue: Suppl. 1
Meeting Dates: 2018 Dec 1-4
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-11-29
Language: English
ACCESSION: WOS:000454837601286
PROVIDER: wos
DOI: 10.1182/blood-2018-99-111946
Notes: Meeting Abstract: 577 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Raajit Kumar Rampal
    351 Rampal
Related MSK Work